ClinicalTrials.gg
CompletedNCT06016972Updated Jan 20, 2025

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

A Phase 2 interventional study of Experimental: QLS-111 ophthalmic solution, (0.015%) and Experimental: QLS-111 ophthalmic solution, (0.03%) in Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes and Primary Open-Angle Glaucoma, Unspecified Eye, sponsored by Qlaris Bio, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Qlaris Bio, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
168th of 279
63 · median 84
Started
2024
with 9 others
Phase 2
76 of 348
5 open now
Registered
291st of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 168th largest by enrollment of the 279 interventional ones that give a count, is one of 10 that started in 2024, is one of 76 in phase 2, and was the 291st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.

Read the detailed description

A randomized, active- and vehicle-controlled, multi-site, double-masked study to evaluate the safety and tolerability of QLS-111 versus vehicle in subjects with primary open-angle glaucoma or ocular hypertension. Primary objective is to evaluate the ocular and systemic safety and tolerability of 3 concentrations of QLS-111 compared to vehicle control. Secondary objective is to evaluate the ocular hypotensive efficacy of 3 concentrations of QLS-111 with once daily morning (QAM), once daily evening (QPM), and twice daily (BID) dosing versus vehicle with QAM, QPM, and BID dosing.

03

Conditions studied

  • Primary Open Angle Glaucoma (POAG)
  • Primary Open Angle Glaucoma of Both Eyes
  • Primary Open-Angle Glaucoma, Unspecified Eye
  • Ocular Hypertension (OHT)

Keywords

  • Qlaris
  • POAG
  • OHT
  • IOP
  • Glaucoma
  • Osprey
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Able to provide written acknowledgement of giving
  • Best corrected visual acuity (BCVA) 20/200 or better Bilateral POAG or OHT with documented historic IOP value(s) ≥24 mmHg, in either eye
  • Post-washout IOP ≥22 mmHg in morning on Visits 2 and 3 and ≥18 mmHg at noon on Visit 2

Exclusion criteria

Exclusion Criteria:

  • IOP >34 mmHg
  • Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications
  • Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1 year from study)
  • Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye
  • Use of other ophthalmic concomitant medications during the study
  • Uncontrolled hypertension or hypotension
  • Significant systemic or psychiatric disease
  • Participation in other trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product
  • Pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    QLS-111 ophthalmic solution

    Qlaris' investigational product, QLS-111 ophthalmic solution, provided in 3 concentrations for this study (0.015%, 0.03%. and 0.075%), single use vials, masked, and preservative free (PF).

    Drug: Experimental: QLS-111 ophthalmic solution, (0.015%) · Drug: Experimental: QLS-111 ophthalmic solution, (0.03%) · Drug: Experimental: QLS-111 ophthalmic solution, (0.075%)

  • Placebo comparator
    QLS-111 ophthalmic vehicle solution

    Inactive control (0.00%). QLS-111 ophthalmic vehicle solution, single use vials, masked, PF.

    Other: QLS-111 ophthalmic vehicle solution

Interventions

  • QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

    Also known as: QLS-111

  • QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

    Also known as: QLS-111

  • QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

    Also known as: QLS-111

  • OtherQLS-111 ophthalmic vehicle solution

    Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

    Also known as: vehicle, placebo

06

What researchers measure

Primary outcomes

  1. Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs)

    Ocular safety and tolerability: adverse events (AEs)

    Time frame: 21 days

  2. Clinically significant change in visual acuity

    Ocular safety and tolerability: visual acuity

    Time frame: 21 days

  3. Clinically significant change in findings on slit lamp exam

    Ocular safety and tolerability: slit lamp

    Time frame: 21 days

  4. Clinically significant change in findings on fundus exam

    Ocular safety and tolerability: fundus

    Time frame: 21 days

  5. Incidence of systemic TEAEs

    Systemic safety and tolerability: AEs

    Time frame: 21 days

  6. Clinically significant changes in blood pressure (BP)

    Systemic safety and tolerability: vital signs

    Time frame: 21 days

  7. Clinically significant changes in heart rate (HR)

    Systemic safety and tolerability: vital signs

    Time frame: 21 days

Secondary outcomes

  1. Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye

    Ocular hypotensive efficacy: diurnal IOP CFB

    Time frame: 21 days

  2. CFB in IOP at various timepoints in the study eye

    Ocular hypotensive efficacy: CFB for multiple timepoints throughout day

    Time frame: up to 21 days

07

Study locations

1 site
  • Coastal Research Associates, LLC
    Roswell, Georgia 30076, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2024, 5 months.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Aug 30, 2023
StartActual
Mar 5, 2024
Primary completionActual
Aug 20, 2024
CompletionActual
Aug 20, 2024
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06016972
Lead sponsor
Qlaris Bio, Inc.
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
Mar 5, 2024
Primary completion
Aug 20, 2024
Completion
Aug 20, 2024
Last update
Jan 20, 2025

Study contacts

Lisa Brandano
study director · Qlaris Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLS-111

Start the discussion